Focus: Natera is a publicly traded diagnostics company specializing in non-invasive prenatal testing, circulating tumor DNA (ctDNA) monitoring, and transplant rejection diagnostics. With 5,001-10,000 employees and $1.1B in FY2025 revenue, it is a scaled leader in precision diagnostics across oncology, women's health, and organ transplantation.
Profile data last refreshed 47m ago · AI intelligence enriched 2w ago
Hot — 222 jobs added in 30d
Net +91 (222 new, 131 removed). Aggressive expansion phase.
Best suited for commercially-focused professionals seeking growth-stage diagnostics exposure; more cautious for those expecting near-term profitability or deep R&D investment.
Flagship oncology product with 10+ clinical trials spanning multiple cancer types, representing core precision oncology strategy.
Help build intelligence for Natera
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Natera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key non-invasive diagnostic for transplant surveillance with Phase 2+ data; addresses significant unmet need in organ transplantation.
Companion diagnostic platform for transplant management with multiple ongoing studies validating clinical utility.
Emerging kidney disease diagnostic supporting renal health monitoring and transplant outcomes.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo